KalVista Pharmaceuticals, Inc. (KALV) has 198 open-market insider trades by 26 insiders since 2017. Over the last six months insiders net sold $1.8M. The most active filer is Christopher Yea.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Novo Holdings A/S | 10% Owner | — | 5 | $45.3M | 2017-10-12 |
| Albert Cha | Dir | — | 5 | $26.3M | 2023-09-11 |
| Bong Y. Koh | 10% Owner | — | 3 | $22.1M | 2024-01-16 |
| SV LIFE Sciences FUND IV Strategic Partners, L. P. | 10% Owner | — | 3 | $17.6M | 2019-04-02 |
| SVLSF Iv, LLC | 10% Owner | — | 3 | $14.8M | 2019-03-18 |
| Venrock Healthcare Capital Partners III, L.P. | 10% Owner | — | 5 | $12.4M | 2026-03-26 |
| Richard Aldrich | Dir | — | 1 | $9.7M | 2017-10-12 |
| Benjamin L. Palleiko | CEO | — | 37 | $8.9M | 2026-05-22 |
| Rajeev M. Shah | Dir10% Owner | — | 1 | $7.2M | 2017-10-12 |
| SV Life Sciences Fund IV (GP), L.P. | 10% Owner | — | 2 | $7.1M | 2019-03-28 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Christopher Yea | — | Sell | $905K | 2026-05-27 |
| Nicole Sweeny | CCO | Sell | $40K | 2026-05-26 |
| Paul K. Audhya | — | Sell | $60K | 2026-05-26 |
| Christopher Yea | — | Sell | $53K | 2026-05-26 |
| Brian Piekos | CFO | Sell | $40K | 2026-05-22 |
| Christopher Yea | — | Sell | $63K | 2026-05-22 |
Companies that share insiders with KALV, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Paul K. Audhya | — | Sell | $72K | 2026-05-22 |
| Benjamin L. Palleiko | CEO | Sell | $293K | 2026-05-22 |
| Nicole Sweeny | CCO | Sell | $50K | 2026-05-22 |
| Paul K. Audhya | — | Sell | $28K | 2026-05-18 |
| Benjamin L. Palleiko | CEO | Sell | $30K | 2026-05-18 |
| Christopher Yea | — | Sell | $30K | 2026-05-18 |
| Benjamin L. Palleiko | CEO | Sell | $89K | 2026-05-12 |
| Paul K. Audhya | — | Sell | $54K | 2026-04-17 |
| Nicole Sweeny | CCO | Sell | $38K | 2026-04-17 |